Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUGCT antisense RNA 1 (SUGCT-AS1) is a human-specific long non-coding RNA transcribed from the antisense strand of the SUGCT gene locus. It is strongly induced in macrophages, particularly under M1 (proinflammatory) polarization stimuli. SUGCT-AS1 acts as a negative feedback regulator in the inflammatory response: when depleted, macrophages secrete higher levels of proinflammatory cytokines such as TNF, IL1B, and IL6, enhancing inflammatory signals in surrounding vascular smooth muscle cells. Mechanistically, SUGCT-AS1 interacts directly with the nuclear protein hnRNPU, modulating its localization and affecting the alternative splicing of MALT1, a mediator of NF-κB signaling. This places SUGCT-AS1 within a novel axis of inflammatory regulation in human macrophages. Its expression and function appear to be specific to humans and are not conserved in the mouse[1][2][3].
Not established. No drugs targeting SUGCT-AS1 are described in available literature. Antisense therapies in general may function by RNA degradation, splicing modulation, or inhibition of RNA interactions[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUGCT antisense RNA 1 (SUGCT-AS1).